Lete-Cel Receives FDA Breakthrough Therapy Designation for Advanced Myxoid/Round Cell Liposarcoma
The FDA granted breakthrough therapy designation to lete-cel for patients with unresectable or metastatic myxoid/round cell liposarcoma.
Related Articles
Dr Levy on the Development and Clinical Use of ADCs in NSCLC
Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer.
COMFORT Studies in Context: Understanding Response Parameters and Long-Term Outcomes
Panelists discuss how the landmark COMFORT trials have shaped the understanding of Janus kinase inhibitor therapy response criteria and long-term clinical outcomes in patients with…
Quantitative IHC Assays May Bridge Gaps in Breast Cancer IHC Test Concordance
David Rimm, MD, PhD, discusses pathology limitations that have been exacerbated by the current lineup of breast cancer IHC tests.
Precision Medicine Heats Up Ahead of SOGO Annual Meeting in GI Cancer
E. Gabriela Chiorean, MD, FASCO, discusses exciting targeted therapies in the GI space and topics to be discussed at the School of Gastrointestinal Oncology meeting.
Senate Finance Committee advances RFK Jr. to likely confirmation, with Bill Cassidy (R-LA) casting the deciding vote – The Cancer Letter
Robert F. Kenedy Jr., an antivaccine advocate and President Trump’s MAHA nominee, has cleared a key hurdle to be confirmed as secretary of Health and…
“Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and gender Medical group sues over removing “information used every day by health professions” – The Cancer Letter
The web page for the FDA Office of Minority Health and Health Equity is no more. To access this subscriber-only content please log in or…
T-DM1 Shows Tolerability in HER2+ Biliary Tract Adenocarcinoma
T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival.
Novel regimen greatly reduced chronic GVHD in phase 2 study at Fred Hutch
A novel drug regimen tested for the first time by researchers at Fred Hutch Cancer Center has shown great promise in preventing moderate to severe…
